Myelodysplastic syndrome in a child with a history of medulloblastoma.
We present a case of myelodysplastic syndrome (MDS) following treatment for medulloblastoma. The tumor was diagnosed at 15 years of age and managed with surgery, craniospinal radiation and a triple-drug regimen [chloroethylnitrosourea (CCNU), vincristine (VCR), procarbazine]. Fifteen months after the completion of therapy, the patient developed MDS with monosomy 5 and monosomy 7 on chromosome analysis of bone marrow cells. Two weeks later, MDS evolved into acute myeloblastic leukemia (AML). Therapy-related MDS or AML may be a complication for patients with past brain tumors. Therefore, they should be carefully followed up by regular physical examinations and complete blood counts.
Akyüz
C
C
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Emir
S
S
Güler
N
N
Tüker
A
A
Büyükpamukçu
M
M
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001856:Bone Marrow Examination; D002528:Cerebellar Neoplasms / Q000628:therapy*; D016371:Cranial Irradiation / Q000009:adverse effects; D017809:Fatal Outcome; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008527:Medulloblastoma / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000209:etiology*; D016609:Neoplasms, Second Primary / Q000209:etiology*; D011344:Procarbazine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D011344:Procarbazine; D014750:Vincristine; D008130:Lomustine